On Monday, Morgan Stanley (NYSE:MS) made a notable change in its rating for shares of Intuitive Surgical (NASDAQ:ISRG), upgrading the stock from Equalweight to Overweight and increasing the price target to $650 from the previous $522. The adjustment reflects the firm's optimism about the company's long-term prospects and its commanding presence in the healthcare robotics sector.
The stock has demonstrated remarkable momentum, delivering a 72% return over the past year and currently trading near its 52-week high of $552.
The financial institution acknowledged the high valuation of Intuitive Surgical's shares, which trade at approximately 48 times 2025 estimated enterprise value to earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) and 69 times price to earnings (P/E). Current metrics from InvestingPro show an EV/EBITDA of 73.7x and P/E of 85.5x, reflecting premium valuations.
Despite these metrics, the analyst highlighted Intuitive Surgical's unique position in the medical technology (MedTech) space, citing the significant barriers to entry in healthcare robotics and the company's strong first-mover advantage. InvestingPro analysis indicates the stock is trading above its calculated Fair Value, with 15+ additional insights available to subscribers.
Intuitive Surgical's da Vinci (EPA:SGEF) surgical systems are noted for their high upfront costs, which create a challenge for competitors as hospitals and healthcare facilities are less likely to switch to new platforms with limited offerings. The firm also pointed to Intuitive Surgical's ability to integrate various business lines into its da Vinci platform, such as the inclusion of insufflation services in its latest model, Dv5.
Morgan Stanley's revised price target is informed by a series of projections, including bear, base, and bull cases for the penetration of robotic surgery in the market. The base case assumes that Intuitive Surgical could capture approximately 80% of the soft tissue robotics market, which is expected to represent about 35% of all soft tissue surgeries within the next 15 years. This scenario suggests a potential 25% upside for the stock from its current level.
The upgrade to Overweight is based on several factors, including the anticipated expansion of surgical indications, increased placements of the Dv5 system leading to growth in the installed base, and a long-term vision of Intuitive Surgical's dominance in the operating room (OR) economy.
InvestingPro data reveals strong fundamentals supporting this outlook, with a 15% revenue growth rate and an impressive 67% gross profit margin. For comprehensive analysis including detailed financial health metrics and growth projections, access the full Pro Research Report, available exclusively to InvestingPro subscribers.
In other recent news, Intuitive Surgical has been drawing attention with its strong financial performance and optimistic projections. The company reported a 17% year-over-year increase in revenue, reaching $2 billion in the third quarter, driven by an 18% rise in DaVinci procedures and robust system placements. The company also adjusted its full-year 2024 procedure growth forecast to a range of 16% to 17%.
Erste Group upgraded Intuitive Surgical's stock rating from Hold to Buy, predicting double-digit percentage growth rates in both sales and profits for 2024 and 2025. This upgrade is backed by the company's superior market position and track record of profitable growth.
Analysts from Piper Sandler, RBC Capital Markets, and Mizuho (NYSE:MFG) Securities have also adjusted their outlooks on Intuitive Surgical, raising their price targets following the company's strong earnings report.
Despite pricing pressures in China, Intuitive Surgical is preparing for a broad launch of DaVinci 5 by mid-2025 and plans to expand the Ion system internationally, especially in China and Europe. These are some of the recent developments for the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.